Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • COMMENT

A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics

Current regulation of T cell receptor (TCR)-based therapeutics may require repeated testing of patients for specific HLA alleles as well as companion diagnostics development, despite the invariant nature of the HLA genotype and availability of robust clinical HLA tests. This increases the burden on patients and the organizations developing these products. We propose regulatory flexibility to facilitate the development of and access to TCR-based therapeutics.
  1. Miriam Meyer

    1. Immatics Biotechnologies GmbH, Tübingen, Germany. M.M. and A.M. contributed equally.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Andrea Mahr

    1. Immatics Biotechnologies GmbH, Tübingen, Germany. M.M. and A.M. contributed equally.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Joanna Brewer

    1. Adaptimmune LLC, Philadelphia, PA, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  4. Volker Daniel

    1. Institute for Immunology, University Hospital Heidelberg, Heidelberg, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  5. Justine Dell‘Aringa

    1. Bristol-Myers Squibb, New York, NY, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  6. Tony Goldstone

    1. HCA Healthcare UK, London, UK.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  7. Sarah Hersey

    1. Bristol-Myers Squibb, New York, NY, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  8. Ian Johnston

    1. Miltenyi Biotec, Bergisch Gladbach, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  9. Pamela Larson

    1. Medigene AG, Martinsried, Planegg, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  10. Michael Loveridge

    1. T-knife Therapeutics, San Francisco, CA, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  11. Gavin MacBeath

    1. TScan Therapeutics, Waltham, MA, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  12. Mark Moyer

    1. Immunocore, Abingdon, UK.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  13. Dirk Nagorsen

    1. Affini-T Therapeutics, Watertown, MA, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  14. Sophie Papa

    1. Enara Bio, Oxford, UK; King’s College London, London, UK.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  15. Leanne Peiser

    1. Bristol-Myers Squibb, New York, NY, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  16. Koustubh Ranade

    1. Immunocore, Abingdon, UK.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  17. Ruben Rizzi

    1. BioNTech SE, Mainz, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  18. Axel Roers

    1. Institute for Immunology, University Hospital Heidelberg, Heidelberg, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  19. Dolores Schendel

    1. Medigene AG, Martinsried, Planegg, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  20. Pallavur Sivakumar

    1. Bristol-Myers Squibb, New York, NY, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  21. Eric Tran

    1. Providence Cancer Institute, Portland, OR, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  22. Özlem Türeci

    1. BioNTech SE, Mainz, Germany; Helmholtz Institute TRON, Mainz, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  23. Luise Weigand

    1. Zelluna Immunotherapy AS, Oslo, Norway.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  24. Anders Wennborg

    1. Miltenyi Biomedicine, Bergisch Gladbach, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  25. Dennis Williams

    1. Adaptimmune LLC, Philadelphia, PA, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  26. Cassian Yee

    1. The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  27. Cedrik M. Britten

    1. Immatics Biotechnologies GmbH, Tübingen, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Introduction

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 23, 1-2 (2024)

doi: https://doi.org/10.1038/d41573-023-00189-4

References

  1. Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385, 1196–1206 (2021).

    Article  PubMed  Google Scholar 

  2. Hong, D. S. et al. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial. Nat. Med. 29, 104–114 (2023).

    Article  PubMed  Google Scholar 

  3. Directorate-General for Health and Food Safety. MDCG 2022-2 - Guidance on general principles of clinical evidence for In Vitro Diagnostic medical devices (IVDs). European Commission https://health.ec.europa.eu/latest-updates/mdcg-2022-2-guidance-general-principles-clinical-evidence-vitro-diagnostic-medical-devices-ivds-2022-01-27_en (2022).

Download references

Supplementary Information

  1. Supplementary information

Competing Interests

The authors declare competing interests, including working for companies that are developing TCR-based therapies. Please see Supplementary information for further details.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links